Abstract
Introduction C3 glomerulopathy (C3G) is a rare but clinically significant glomerulopathy. However, little is known about its transcriptomic profile. We investigated the substructure-specific gene expression profile of C3G using the recently introduced spatial transcriptomics technology.
Methods We performed spatial transcriptomic profiling using GeoMx Digital Spatial Profiler with formalin-fixed paraffin-embedded kidney biopsy specimens of three C3G cases and seven controls from donor kidney biopsy. Additionally, 41 samples of other glomerulonephritis, including focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease, were included as disease controls. Gene expression levels were compared by DESeq2 method to identify differentially expressed genes (DEGs). We performed gene ontology (GO) annotation through the ToppGene suite and mapped interactions among the DEGs using the STRING database.
Results We identified 229 and 157 highly expressed DEGs in the glomeruli of C3G compared to those of donor and disease controls, respectively, with consistently highest fold changes in POSTN, COL1A2, and IFI44L. Protease binding, structural molecule activity, and extracellular matrix structural constituent were among the top enriched GO terms in the glomeruli of C3G, with consistent features seen in the network analysis. In contrast, no significant GO enrichment was found among the 563 and 347 lowly expressed DEGs in the glomeruli of C3G compared to the controls. The tubulointerstitial transcriptomic profiles of C3G were similar to those of the controls.
Conclusion In the glomerulus of C3G, genes related to the extracellular matrix and interferon activity were the most upregulated. Significant disease-specific transcriptomic alterations in C3G provide potential insights into the pathophysiology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, Ministry of Science and ICT) (No. 2021R1A2C2094586) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (2022M3A9D3016848).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Seoul National University Hospital waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
